(via Thenewswire.ca)

Ottawa, ON / TheNewswire / February 11, 2016 - Avivagen Inc. (TSXV: VIV, OTC Pink: CHEXF), a life sciences company that develops and delivers products intended to replace the antibiotics used in livestock feeds, announces the start of a trial with UNAHCO, Inc. at the University of the Philippines Los Banos to measure the benefits of OxC-beta(TM) Livestock (OxC-beta) as a feed additive for broiler poultry.

Trial design was by way of collaboration between Avivagen and UNAHCO and it will measure the benefits of OxC-beta on the performance and welfare of broiler poultry raised under typical local commercial production conditions for their full growth cycle. Response to the addition of OxC-beta into feed will be recorded via a series of health and commercial measures including, but not limited to, final body weight, average daily weight gain, feed conversion ratios and tissue/gut morphology. Testing will include six study arms, including un-medicated and medicated control groups and OxC-beta alone or in combination with medications.

UNAHCO is the wholly-owned feed and veterinary subsidiary of Unilab Inc., the biggest pharmaceutical company in the Philippines. UNAHCO provides a broad range of animal healthcare and nutrition products and programs to meet the requirements of both commercial and backyard farmers in the Philippines as well as abroad. It is a leading producer of pig and poultry feed and has a distribution network that serves more than 3,000 outlets, supported by more than 100 field personnel.

U.P. Los Banos is a major public university located southeast of Manila that plays an influential role in Asian agriculture and biotechnology. The university hosts nine specialty colleges, local and international research and has emphasized agriculture since its founding in 1909. The referenced trial will be conducted at the farm facilities of U.P. Los Ba n os.

Glen Ibanez, AVP-Technical Services of UNAHCO, said "This project will further strengthen UNAHCO's green platform strategy 'Safe Feed = Safe Food'. We're very excited to work with Avivagen on their OxC-beta(TM) Technology, a nature-based feed ingredient that has been shown to enhance immunity and productivity."

Cameron Groome, CEO and President of Avivagen, provided its perspectives, "We're very pleased to be collaborating with UNAHCO for this new broiler poultry trial: The Philippines is an important Asian market and both UNAHCO and U.P. Los Banos are rightly respected for their capabilities. We believe that positive results from such trials will help establish OxC-beta(TM) Technology as a valuable new tool for commercial feed and livestock producers."

About the Philippines

The Republic of the Philippines is made up of over 7,000 islands with a population of approximately 100 million over its 300,000 square kilometers of land. Filipino and English are the official languages and annual GDP growth exceeds 5%. Agriculture is an important segment of the national economy with domestic livestock feed consumption estimated at 12 million metric tons per year. Swine production is the largest feed market segment, followed by broiler poultry.

About Avivagen Inc.

Avivagen Inc. is a life sciences company listed on the TSX Venture Exchange under the ticker symbol "VIV" and on OTC Pink as "CHEXF." The Company is developing scientifically-proven products for replacing antibiotics in livestock feeds and to benefit human and animal health. Its target markets include enhancing productivity and health in livestock, companion animal quality-of-life, and maintaining optimal health in humans.

Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com .

About Avivagen's Technology

Avivagen's proprietary and patented technology derives from its discovery that carotenoid oxidation naturally produces oxygen copolymer products that have beneficial immunological properties. Avivagen's commercial-stage application of its inventions is fully oxidized beta-carotene, OxC-beta(TM) Technology (OxC-beta). Equivalents to the active constituents in OxC-beta occur naturally in plant-based food products, but in widely varying amounts. Avivagen has discovered that OxC-beta can help an animal's own systems to maintain and enhance health by supporting immune function and calming excess inflammation. OxC-beta is being developed to replace the antibiotics used for disease prevention and growth promotion in livestock feeds, to enhance the quality of life of companion animals and to help maintain optimal health in humans. Avivagen's commercial products are OxC-beta(TM) Livestock (Kingdom of Thailand), Vivamune(TM) Vital Health 3 Chews (U.S.) and Oximunol(TM) Chewable Tablets (U.S.).

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "aim", "anticipate", "appear", "believe", "consider", "could", "estimate", "expect", "if", "intend", "goal", "hope", "likely", "may", "plan", "possibly", "potentially", "pursue", "seem", "should", "whether", "will", "would" and similar expressions. Statements about uses of the technologies described in this news release, including their importance to animal or human health, their novelty, safety, efficacy or affordability, about UNAHCO, Inc., Unilab Inc. or U.P. Los Banos, the nature of the trial conditions, the timing, intentions or relevance of the trial and whether trial results will help support product registration or enhance commercial adoption, are all forward looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Such Avivagen risks and uncertainties include, but are not limited to, the following: its ability to continue as a going concern; the results of ongoing or future trials may not be positive or sufficiently positive; even if the results of trials are positive, there is no guarantee that its products will be commercially successful or that requisite regulatory approvals will be obtained; the timing and results of trials may be delayed or may not be completed at all; and intellectual property rights may prove inadequate to protect its inventions. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.

Cameron Groome, CEO & President
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164 Website: www.avivagen.com

Copyright (C) 2016 Avivagen Inc.

OxC-beta(TM), Vivamune(TM) and Oximunol(TM) are trademarks of Avivagen Inc.

Copyright (c) 2016 TheNewswire - All rights reserved.